Preclinical screening of anticancer drugs using infrared (IR) microspectroscopy

Caryn Hughes; Graeme Clemens; Matthew J Baker

doi:10.1016/j.tibtech.2015.03.010

Preclinical screening of anticancer drugs using infrared (IR) microspectroscopy

Trends Biotechnol. 2015 Aug;33(8):429-30. doi: 10.1016/j.tibtech.2015.03.010. Epub 2015 Apr 10.

Authors

Caryn Hughes¹, Graeme Clemens², Matthew J Baker³

Affiliations

¹ University of Manchester, Brunswick Street, Manchester M13 9PL, UK; WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK. Electronic address: [email protected].
² WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK; Centre for Materials Science, Division of Chemistry, School of Forensic and Investigative Sciences, University of Central Lancashire (UCLan), Preston PR1 2HE, UK.
³ WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, UK. Electronic address: [email protected].

PMID: 25869233
DOI: 10.1016/j.tibtech.2015.03.010

Abstract

High-throughput label-free technologies such as IR microscopy can objectively assess the effect of drugs upon cellular systems, offering the potential of a valuable preclinical tool that can aid in the drug development process.

Keywords: biomarker; cancer; high-throughput; infrared; preclinical screening; spectroscopy.

MeSH terms

Animals
Antineoplastic Agents / toxicity*
Cell Survival / drug effects
Cells, Cultured
Drug Evaluation, Preclinical / methods*
Microscopy / methods*
Spectroscopy, Fourier Transform Infrared / methods*

Substances

Antineoplastic Agents